Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2860-2867

  Delaney, Carol A ^a   Wang, Lan Z ^a   Kyle, Suzanne ^a   White, Alex W ^b   Calvert, A Hilary ^a   Curtin, Nicola J ^a   Durkacz, Barbara W ^a   Hostomsky, Zdenek ^c   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL)BENZAMIDAZOLE 4 CARBOXAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; 8 HYDROXY 2 METHYLQUINAZOLIN 4 [3H]ONE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NU 1085; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; COLON CANCER; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; DACARBAZINE; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033941729     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lautier, D., Lagueux, J., Thibodeau, J., Menard, L., and Poirier, G. G. Molecular and biochemical features of poly(ADP-ribose) metabolism. Mol. Cell. Biochem., 122: 171-193, 1993.
2. de Murcia, G., and Ménissier de Murcia, J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci., 19: 172-176, 1994.
3. Lindahl, T., Satoh, M. S., Poirier, G. G., and Klungland, A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biol. Sci., 20: 405-411, 1995.
4. Miwa, M., and Sugimura, T. Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-ribose) by a calf thymus extract. J. Biol. Chem., 246: 6362-6364, 1971.
5. Berger, N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res., 101: 4-15, 1985.
6. Boulton, S., Pemberton, L. C., Porteous, J. K., Curtin, N. J., Griffin, R. J., Golding, B. T., and Durkacz, B. W. Potentiation of temozolomide cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 72: 849-856, 1995.
7. Trucco, C., Oliver, F. J., de Murcia, G., and Ménissier de Murcia, J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res., 26: 2644-2649, 1998.
8. Malanga, M., Pleschke, J. M., Kleczkowska, H. E., and Althaus, F. R. Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. J. Biol. Chem., 273: 11839-11843, 1998.
9. Agarwal, M. L., Argarwal, A., Taylor, W. R., Wang, Z-Q., Wagner, E. F., and Stark, G. R. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose-polymerase. Oncogene, 15: 1035-1041, 1997.
10. Pieper, A. A., Verma, A., Zhang, J., and Snyder, S. H. Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci., 20: 171-181, 1999.
11. Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., De La Rubia, G., Oliver, J., Rolli, V., Ménissier-de Murcia, J., and de Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 81: 69-75, 1999.
12. Boulton, S., Kyle, S., and Durkacz, B. W. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis (Lond.), 20: 199-203, 1999.
13. D'Silva, I., Pellletier, J. D., Lagueux, J., D'Amours, D., Chaudhry, M. A., Weinfield, M., Lees-Miller, S. P., and Poirier G. G. Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. Biochim. Biophys. Acta, 1430: 119-126, 1999.
14. Morrison, C., Smith, G. C. M., Sting, L., Jackson, S. P., Wagner, E. F., and Wang, Z-Q. Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat. Genet., 17: 479-482, 1997.
15. Wang, Z-Q., Auer, B., Sting, L., Berghammer, H., Haidacher, D., Schweiger, M., and Wagner, E. F. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev., 9: 509-520, 1995.
16. Ménissier de Murcia, J., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, M., Mark, B., Oliver, J., Masson, M., Dierich, A., LeMeur, M., Waltzinger, C., Chambon, P., and de Murcia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and cells. Proc. Natl. Acad. Sci. USA, 94: 7303-7307, 1997.
17. Griffin, R. J., Curtin, N. J., Golding, B. T., Durkacz, B. W., and Calvert, A. H. The role of inhibitors of poly(ADP-ribose) polymerase as resistance modifying agents in cancer therapy. Biochimie, 77: 408-422, 1995.
18. Griffin, R. J., Pemberton, L. C., Rhodes, D., Bleasdale, C., Bowman, K., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Newell, D. R., Porteous, J. K., and Golding, B. T. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Anti-Cancer Drug Des., 10: 507-514, 1995.
19. Griffin, R. J., Srinivasan, S., White, A. W., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., and Golding, B. T. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme, poly (ADP-ribose) polymerase. Pharm. Sci., 2: 43-47, 1996.
20. Griffin, R. J., Srinivasan, S., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., and Golding, B. T. Resistance-modifying agents. 5. Synthesis and biological properties of quinazoline inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J. Med. Chem., 41: 5247-5256, 1998.
21. Bowman, K. J., White, A., Golding, B. T., Griffin, R. J., and Curtin, N. J. Potentiation of anti-cancer agent cytotoxicity by the potent poly-(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer, 78: 1269-1277, 1998.
22. Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hoffman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br. J. Cancer, 65: 271-291, 1992.
23. Mattern, M. R., Mong, S-M., Bartus, H. F., Mirabelli, C. K., Crooke, S. T., and Johnson, R. K. Relationship between the intracellular effects of camptothecin and the inhibition of topoisomerase I in cultured L1210 cells. Cancer Res., 47: 1793-1798.
24. Beidler, D. R., Chang, J-Y., Zhou, B., and Cheng, Y. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res., 56: 345-353.
25. Bowman, K., Calvert, A. H., Curtin, N. J., Golding, B. T., Griffin, R. J., Newell, D. R. Srinivasan, S., and White, A. Effect of novel poly(ADP-ribose) polymerase inhibitors on the cytotoxicity of anticancer agents. Br. J. Cancer, 73(Suppl. 26, No. 3.6): 13, 1996.
26. Pratt, C. B., Stewart, C. F., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heidman, R., Sandlund, J. T., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
27. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Bell, B., Grier, H., and Vietti, T. J. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumours: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol., 18: 352-361, 1996.
28. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A., Jr., J., and Kohn, K. W. Characterisation of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
29. 1/S boundary after irradiation. Oncogene, 12: 875-882, 1996.
30. Arita, D., and Ryunosuke, K. Apoptosis induced by VP-16 independent of p53 and its mechanism in human colon cancer cell lines. Biotherapy, 10: 457-459, 1996.
31. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
32. Chen, T. R. In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res., 104: 255-262, 1977.
33. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Wareen, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
34. Tsang, L. L. H., Quarterman, C. P., Gescher, A., and Slack, J. A. Comparison of the cytotoxicity in vitro of temozolomide and decarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol., 27: 342-346, 1991.